Navigation Links
Product Differentiation to Boost European Human Growth Hormones Market, Says Frost & Sullivan
Date:3/6/2013

LONDON, March 6, 2013 /PRNewswire/ -- The stable growth of the European human growth hormone (hGH) market is attributed primarily to a decrease in the prices and an increase in the overall volumes of hGH drugs used.

No new indications for hGH therapy are likely to be approved by the European Medicines Agency (EMEA) over the next 3 to 5 years. This, paralleled by a stable patient population, has resulted in a saturated market that does not provide attractive opportunities for new entrants. Nevertheless, product differentiation based on innovative technologies will enable existing market participants to expand their share in this highly concentrated market.

New analysis from Frost & Sullivan (http://www.lifesciences.frost.com), European Human Growth Hormones Market, finds that the market earned $0.99 billion in 2012 and estimates this to reach $1.22 billion in 2019. The research covers adult and paediatric segments.

"Product differentiation in the hGH market is aimed at 3 different levels; namely, drug delivery mechanisms, long-acting preparations and improved formulations, and combination therapy," notes Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. "Companies have increasingly started to focus on developing non-invasive delivery methods to improve patient compliance and reduce treatment withdrawal rates."

Such efforts are set to address the issue of reduced therapeutic efficacy due to poor patient compliance. With more than 80% of the target population for hGH being children below the age of 15 years, taking hGH injections on a daily basis is a major challenge. This has led to poor adherence and higher withdrawal rates from existing therapeutic regimes.

Entering into strategic collaborations with drug delivery companies could pave the way for product differentiation, while enabling market participants to gain a competitive advantage.

"Fostering strategic alliances with technology providers and drug delivery companies will help hGH manufacturers to develop other potential modes of drug delivery such as oral and pulmonary," concludes Chidambaram. "Such non-invasive drug delivery methods are likely to motivate improved patient compliance and treatment success rates."

If you are interested in more information on this research, please send an email to Anna Zanchi , Corporate Communications, at anna.zanchi@frost.com

European Human Growth Hormones Market is part of the Life Sciences Growth Partnership Service programme. Frost & Sullivan's related research services include: European Biosimilars Market, European Vaccines Market, and European Pharmaceutical and Biotech Contract Manufacturing Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion
Join Us:           Join our community
Subscribe:       Newsletter on "the next big thing"
Register:         Gain access to visionary innovation

Contact
Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com
http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Diabetes Research Institute Tests BioHub Mini Organ to Restore Natural Insulin Production in Type 1 Diabetes
2. Nutrastar International Completes Multi-Year Production Expansion Project Bringing Cordyceps Capacity to 100 Tons
3. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
4. MD Buylines User Satisfaction Report Awards MGC Diagnostics Pulmonary Function Products Top Rating for Fourth Consecutive Quarter
5. SurgiCount Medical Launches New Surgical Sponge Product
6. Longitudinal Study Highlights Evolving Role of Medical Science Liaisons with Thought Leaders and Product Development
7. GPMG Product Helps Medical Device Specification Developers be FDA and ISO 13485 Compliant
8. BiOptix to highlight new carbonic anhydrase data at IBCs Biopharmaceutical Development & Production Week
9. GPMG Unveils a Quality System Product Designed for Initial Importers of Medical Devices
10. Asthmapolis Wins Bluetooth Breakthrough Product Award
11. Glide Pharma Completes £14.0 Million ($21.4 Million) Fundraising for Scale Up of Drug and Device Manufacturing Processes and Product Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für ... Apothekenbundes von Kenia eingeführt. Continue Reading ... ... Test! (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical wurde durch die ...
(Date:12/2/2016)... , December 2, 2016 Orthopedic Implants ... Support) is Expected to Gain a Significant Market Share Owing ... Ailments  ... According to a new ... Medical Implants Sterile Packaging: Clamshell Product Type Segment Projected to ...
(Date:12/2/2016)... December 2, 2016 On Thursday, the ... in red, while the Dow Jones Industrial Average managed to ... of US markets, which prompted Stock-callers this morning to look ... (NASDAQ: NUVA ), Smith & Nephew PLC (NYSE: ... NXTM ), and Cesca Therapeutics Inc. (NASDAQ: KOOL ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative ... National Family Partnership and the Drug Enforcement Administration as part of the National Red ... 10 winning schools who decorated their campuses with this year’s Red Ribbon Week theme: ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... they now offer a comprehensive in-house dental plan for all patients. Understanding that ... a plan that gives patients a number of perks, including discounts on many ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... Deloitte Wisconsin 75, an annual ranking and recognition of the largest closely held ... list, having ranked from 2008-2016. In addition, Standard Process was awarded the Talent ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For ... announced the opening of a new residential mental health treatment program in Chino ... issues such as severe anxiety, depression, bi-polar disorder, and other related issues. , ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... and stylish design wanted by today’s consumers at an affordable price, is now ... says the new watch is “a game changer” when it comes to the ...
Breaking Medicine News(10 mins):